Prior to emergence of the Omicron SARS-CoV-2 variant, and at the time of the issuance of the Emergency Use Authorization (EUA) for the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine, the efficacy of 2 doses of the 30-µg vaccine in adolescents 12 to 15 years of age and of the 10-µg dose in children 5 to 11 years of age were 100% (95% CI, 75.3%-100%) and 90.7% (95% CI, 67.7%-98.3%), respectively. However, 2 studies published in this issue of JAMA demonstrate that the estimated vaccine effectiveness among children and adolescents with Omicron is considerably lower than in the initial studies, and protection wanes rapidly, especially with the novel SARS-CoV-2 variants.
Source: JAMA Online First